• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于人工智能和云的诊断系统进行全覆盖宫颈癌筛查方案的表现:超大规模人群的观察性研究。

Performance of a Full-Coverage Cervical Cancer Screening Program Using on an Artificial Intelligence- and Cloud-Based Diagnostic System: Observational Study of an Ultralarge Population.

机构信息

School of Medicine and Health Management, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

The Fifth Hospital of Wuhan, Wuhan, China.

出版信息

J Med Internet Res. 2024 Nov 20;26:e51477. doi: 10.2196/51477.

DOI:10.2196/51477
PMID:39566061
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11618014/
Abstract

BACKGROUND

The World Health Organization has set a global strategy to eliminate cervical cancer, emphasizing the need for cervical cancer screening coverage to reach 70%. In response, China has developed an action plan to accelerate the elimination of cervical cancer, with Hubei province implementing China's first provincial full-coverage screening program using an artificial intelligence (AI) and cloud-based diagnostic system.

OBJECTIVE

This study aimed to evaluate the performance of AI technology in this full-coverage screening program. The evaluation indicators included accessibility, screening efficiency, diagnostic quality, and program cost.

METHODS

Characteristics of 1,704,461 individuals screened from July 2022 to January 2023 were used to analyze accessibility and AI screening efficiency. A random sample of 220 individuals was used for external diagnostic quality control. The costs of different participating screening institutions were assessed.

RESULTS

Cervical cancer screening services were extended to all administrative districts, especially in rural areas. Rural women had the highest participation rate at 67.54% (1,147,839/1,699,591). Approximately 1.7 million individuals were screened, achieving a cumulative coverage of 13.45% in about 6 months. Full-coverage programs could be achieved by AI technology in approximately 1 year, which was 87.5 times more efficient than the manual reading of slides. The sample compliance rate was as high as 99.1%, and compliance rates for positive, negative, and pathology biopsy reviews exceeded 96%. The cost of this program was CN ¥49 (the average exchange rate in 2022 is as follows: US $1=CN ¥6.7261) per person, with the primary screening institution and the third-party testing institute receiving CN ¥19 and ¥27, respectively.

CONCLUSIONS

AI-assisted diagnosis has proven to be accessible, efficient, reliable, and low cost, which could support the implementation of full-coverage screening programs, especially in areas with insufficient health resources. AI technology served as a crucial tool for rapidly and effectively increasing screening coverage, which would accelerate the achievement of the World Health Organization's goals of eliminating cervical cancer.

摘要

背景

世界卫生组织制定了全球消除宫颈癌战略,强调宫颈癌筛查覆盖率需达到 70%。为响应号召,中国制定了加速消除宫颈癌行动计划,湖北省采用人工智能(AI)和基于云的诊断系统实施了中国首个省级全覆盖筛查项目。

目的

本研究旨在评估 AI 技术在该全覆盖筛查项目中的表现。评估指标包括可及性、筛查效率、诊断质量和项目成本。

方法

分析了 2022 年 7 月至 2023 年 1 月间 1704461 名筛查者的特征,以评估可及性和 AI 筛查效率。随机抽取 220 名进行外部诊断质量控制。评估了不同参与筛查机构的成本。

结果

宫颈癌筛查服务扩展到所有行政区域,尤其是农村地区。农村女性的参与率最高,为 67.54%(1147839/1699591)。约 170 万人接受了筛查,在大约 6 个月内累计覆盖率达到 13.45%。AI 技术可在大约 1 年内实现全覆盖项目,效率比手动阅片高 87.5 倍。样本符合率高达 99.1%,阳性、阴性和病理活检复查符合率均超过 96%。该项目的成本为每人 49 元人民币(2022 年平均汇率为 1 美元=6.7261 元人民币),初筛机构和第三方检测机构分别收取 19 元和 27 元。

结论

AI 辅助诊断具有可及性、高效、可靠和低成本的特点,能够支持全覆盖筛查项目的实施,尤其是在卫生资源不足的地区。AI 技术是快速有效提高筛查覆盖率的关键工具,有助于实现世界卫生组织消除宫颈癌的目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b1c/11618014/7388bb22e931/jmir_v26i1e51477_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b1c/11618014/7cc3024246c5/jmir_v26i1e51477_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b1c/11618014/7388bb22e931/jmir_v26i1e51477_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b1c/11618014/7cc3024246c5/jmir_v26i1e51477_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b1c/11618014/7388bb22e931/jmir_v26i1e51477_fig2.jpg

相似文献

1
Performance of a Full-Coverage Cervical Cancer Screening Program Using on an Artificial Intelligence- and Cloud-Based Diagnostic System: Observational Study of an Ultralarge Population.基于人工智能和云的诊断系统进行全覆盖宫颈癌筛查方案的表现:超大规模人群的观察性研究。
J Med Internet Res. 2024 Nov 20;26:e51477. doi: 10.2196/51477.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
6
[Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].[卫生技术评估报告。液基细胞学在宫颈癌前病变筛查中的应用]
Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33.
7
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Cervical Cancer Screening, HPV Vaccination, and Cervical Cancer Elimination.宫颈癌筛查、人乳头瘤病毒疫苗接种与宫颈癌消除
JAMA Netw Open. 2025 Aug 1;8(8):e2526683. doi: 10.1001/jamanetworkopen.2025.26683.
10
Diagnostic Performance of Universal versus Stratified Computer-Aided Detection Thresholds for Chest X-Ray-Based Tuberculosis Screening.基于胸部X光的肺结核筛查中通用与分层计算机辅助检测阈值的诊断性能
medRxiv. 2025 Apr 10:2025.04.09.25325458. doi: 10.1101/2025.04.09.25325458.

引用本文的文献

1
Recent advances in applications of machine learning in cervical cancer research: a focus on prediction models.机器学习在宫颈癌研究中的应用新进展:聚焦预测模型
Obstet Gynecol Sci. 2025 Jul;68(4):247-259. doi: 10.5468/ogs.25041. Epub 2025 May 29.

本文引用的文献

1
Cancer incidence and mortality in China, 2016.2016年中国癌症的发病率和死亡率
J Natl Cancer Cent. 2022 Feb 27;2(1):1-9. doi: 10.1016/j.jncc.2022.02.002. eCollection 2022 Mar.
2
Strategies to eliminate cervical cancer in China.中国消除宫颈癌的策略。
Front Oncol. 2023 Jun 2;13:1105468. doi: 10.3389/fonc.2023.1105468. eCollection 2023.
3
Cost-effectiveness of artificial intelligence-assisted liquid-based cytology testing for cervical cancer screening in China.人工智能辅助液基细胞学检测在中国宫颈癌筛查中的成本效益
Lancet Reg Health West Pac. 2023 Mar 3;34:100726. doi: 10.1016/j.lanwpc.2023.100726. eCollection 2023 May.
4
Cervical cancer screening aided by artificial intelligence, China.人工智能辅助宫颈癌筛查,中国。
Bull World Health Organ. 2023 Jun 1;101(6):381-390. doi: 10.2471/BLT.22.289061. Epub 2023 May 1.
5
Cervical Cancer Screening Coverage - China, 2018-2019.2018 - 2019年中国宫颈癌筛查覆盖率
China CDC Wkly. 2022 Dec 2;4(48):1077-1082. doi: 10.46234/ccdcw2022.217.
6
Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Cervical Cancer - China, 2003-2017.2003 - 2017年中国宫颈癌发病率、死亡率及年龄 - 时期 - 队列效应趋势
China CDC Wkly. 2022 Dec 2;4(48):1070-1076. doi: 10.46234/ccdcw2022.216.
7
Achieving equitable access to cancer screening services to reduce the cancer burden in the Asia-Pacific region: Experience from Hong Kong.在亚太地区实现公平获得癌症筛查服务以减轻癌症负担:香港的经验
Lancet Reg Health West Pac. 2022 Sep 8;29:100587. doi: 10.1016/j.lanwpc.2022.100587. eCollection 2022 Dec.
8
Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.全球 202 个国家和地区的宫颈癌筛查规划和年龄别覆盖估计:综述和综合分析。
Lancet Glob Health. 2022 Aug;10(8):e1115-e1127. doi: 10.1016/S2214-109X(22)00241-8.
9
Artificial Intelligence in Cervical Cancer Screening and Diagnosis.人工智能在宫颈癌筛查与诊断中的应用
Front Oncol. 2022 Mar 11;12:851367. doi: 10.3389/fonc.2022.851367. eCollection 2022.
10
Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.基于人群的宫颈癌筛查项目中适龄 HPV 初筛与细胞学检查效果比较:一项全国性的横断面研究
Cancer Commun (Lond). 2022 Mar;42(3):191-204. doi: 10.1002/cac2.12256. Epub 2022 Feb 10.